Pathologic Complete Response Achieved in Early-Stage HER2-Positive Breast Cancer After Neoadjuvant Therapy With Trastuzumab and Chemotherapy vs. Trastuzumab, Chemotherapy, and Pertuzumab: A Systematic Review and Meta-Analysis of Clinical Trials

Patients diagnosed with human epidermal growth factor receptor 2 (HER2)-positive breast cancer require treatment upfront because of the aggressive nature of this type of cancer. Patients with early-stage HER2-positive breast cancer are usually treated with neoadjuvant therapy. This neoadjuvant thera...

Descripción completa

Detalles Bibliográficos
Autores principales: Fazal, Faizan, Bashir, Muhammad Nauman, Adil, Maham Leeza, Tanveer, Usama, Ahmed, Mansoor, Chaudhry, Taha Zahid, Ijaz, Ali Ahmad, Haider, Muhammad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Internal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10312476/
https://www.ncbi.nlm.nih.gov/pubmed/37398703
http://dx.doi.org/10.7759/cureus.39780

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10312476/
https://www.ncbi.nlm.nih.gov/pubmed/37398703
http://dx.doi.org/10.7759/cureus.39780

Ejemplares similares